OPV117059: A Long-Term Extension Study of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris

Trial Profile

OPV117059: A Long-Term Extension Study of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Antihistamines; Paracetamol; Prednisolone
  • Indications Pemphigus vulgaris
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 17 Jun 2016 Status changed from withdrawn prior to enrolment to discontinued.
    • 12 May 2016 Status changed from discontinued to withdrawn prior to enrolment.
    • 08 Mar 2016 According to Genmab media release, this study will be discontinued as company wants to focus on relapsing multiple sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top